# Oruka Therapeutics (ORKA) — News ORKA · NASDAQ · Stock Canonical page: https://www.lighthorse.io/tickers/orka/news ## Recent headlines - [Europe's STOXX 600 pares gains after US CPI, last up 0.46%](https://www.ainvest.com/news/europe-stoxx-600-pares-gains-cpi-0-46-2610) — AInvest Wire, Oct 14, 2026 European stocks trimmed gains on Thursday as investors digested the latest U.S. inflation data, which showed a 0.4% rise in consumer prices for January, bringing the annual rate to 7.2% . The pan-European STOXX 600 index had earlier risen 0.46% but pared those gains as traders weighed the… - [Orora: For SaveGlass, ongoing impacts from US tariffs, accelerated effects of Middle East conflict resulted in adverse price and mix effects in 2H26](https://www.ainvest.com/news/orora-saveglass-ongoing-impacts-tariffs-accelerated-effects-middle-east-conflict-resulted-adverse-price-mix-effects-2h26-2610) — AInvest Wire, Oct 13, 2026 Orora has reported adverse price and mix effects in the second half of 2026, primarily attributed to ongoing impacts from U.S. tariffs and the accelerated effects of the Middle East conflict. These factors have disrupted supply chains and altered market dynamics, particularly in the glass… - [Halozyme Therapeutics, Inc.: H.C. Wainwright raises target price to $130 from $115](https://www.ainvest.com/news/halozyme-therapeutics-wainwright-raises-target-price-130-115-2610) — AInvest Wire, Oct 8, 2026 H.C. Wainwright has raised its price target for Oruka Therapeutics (ORKA) to $130 from $115, maintaining a Buy rating for the stock. This upgrade follows a series of developments that have bolstered investor confidence in Oruka’s clinical pipeline and strategic partnerships. Among the most… - [Oruka Therapeutics - 52-week Everlast-A data expected in December 2026](https://www.ainvest.com/news/oruka-therapeutics-52-week-everlast-data-expected-december-2026-2609) — AInvest Wire, Sep 23, 2026 Oruka Therapeutics, Inc. is anticipated to release 52-week data for its Everlast-A program in December 2026, according to current expectations. This milestone follows ongoing clinical development efforts and represents a key step in the company’s pipeline advancement. Investors and stakeholders are… - [Oruka Therapeutics - Two serious adverse events reported, neither deemed drug related](https://www.ainvest.com/news/oruka-therapeutics-adverse-events-reported-deemed-drug-related-2609) — AInvest Wire, Sep 23, 2026 Oruka Therapeutics, Inc. has disclosed two serious adverse events in its clinical trials, according to a recent release from the company’s investor relations department. The events, which occurred during ongoing studies, were evaluated by the company’s medical and safety teams. Following a thorough… --- Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).